Following its prior receipt of FDA Breakthrough Therapy Designation (BTD) for the treatment of Primary Biliary Cholangitis (PBC), the self-developed Class 1 new drug CS0159 oral tablet from Cascade has now also received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) f
July 24, 2025, Shanghai – Cascade announced that its self-developed Class 1 new drug, the CS0159 oral tablet, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA). Based on CS0159's outstanding clinical potential in treating Primary Biliary Cholan
On August 22, 2024, Cascade Pharmaceuticals announced the official launch of a Phase I clinical trial for its THR-β agonist, CS060380.The trial, titled "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single and Multiple Ascending Doses of CS060380 in Healthy Subjects and Participants with Elevated LDL-C", successfully held its kickoff meeting at Xuhui Central Hospital in Shanghai.
Recently, Cascade Pharmaceuticals announced that its independently developed Class I new drug, CS060304, has received implicit approval for clinical trial application (IND) from the U.S. Food and Drug Administration (FDA).About CS060304CS060304 is a small molecule agonist targeting thyroid receptor
Cascade recently announced thatthe new FXR agonist CS0159, jointly developed by the team of Eric Xu, founder of Shanghai Institute of Medicine, and Li Jia, team of Shanghai Institute of Medicine, is aimed at NASH-CS0159-002 carried out in the United States for non-alcoholic fatty liver disease
沪ICP备88888888号
